Eric Sagonowsky is a Senior Editor at Fierce Life Sciences. He covers a range of topics within medicine and healthcare, alternative medicine, and business economics, with a particular focus on the FDA, Coronavirus, and leading biotech companies like Moderna and AstraZeneca. Eric's insights and analyses have been featured in Biotech and Fierce Pharma.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Eric Sagonowsky's articles predominantly cover announcements from the healthcare and pharmaceutical sectors, with a focus on FDA approvals, drug companies, medical research, and broader healthcare topics. His coverage suggests he would likely be interested in receiving pitches related to new drug approvals, clinical trial results or significant developments within pharmaceutical companies.
Given his extensive press release coverage (28%), Eric is likely open to receiving news directly from pharmaceutical companies about their latest products and milestones. Additionally, given the emphasis on government announcements (16%), he might also be interested in regulatory changes impacting the industry.
Since there is no specified geographic focus for Eric's coverage area, it can be inferred that he covers global developments within the pharmaceutical and healthcare industries.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Eric Sagonowsky
Lilly's dual GIP/GLP-1 receptor agonist tirzepatide has already demonstrated its benefits in patients with
The TROP2 antibody-drug conjugate race has heated up among three Big Pharma companies: Gilead Sciences, AstraZeneca and Merck.
By: James Waldron, Eric Sagonowsky
After revealing plans to hit the U.S. public markets less than a month ago, Zenas Biopharma and Bicara Therapeutics have mapped out the details behind their planned initial public offerings.
By: Eric Sagonowsky
No large pharma company has traversed this decade's ups and downs quite like Pfizer. As the company rolls ahead with a large restructuring campaign, some staffers in Ireland will soon feel the effects.
By: Eric Sagonowsky
On the same day as Roche's Pharma Day in London, the biopharma giant revealed a high-dollar deal with Chinese-American biotech Regor for the latter's CDK inhibitors. Meanwhile, Legend's momentum continued with a strong survival showing for Johnson & Johnson-partnered CAR-T Carvykti and the announcement of a planned R&D facility in the U.S. In addition, SK pharmteco is plotting a manufacturing expansion. Plus more.
By: Eric Sagonowsky
Ever since the FDA rejected zuranolone in major depressive disorder last year, brain health specialist Sage Therapeutics has been somewhat in flux.
By: Eric Sagonowsky
Following reports of an ex-AstraZeneca executive being detained in China, the company acknowledged that its current president in the country, Leon Wang, "is cooperating with an ongoing investigation."
By: Eric Sagonowsky
The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is planning more than 100 cuts at its corporate headquarters.
By: Eric Sagonowsky
Merck and Johnson & Johnson are cutting staffers in China as they face local headwinds, according to reports. Australia's CSL is winding down operations at a cell and gene therapy R&D site in California. Kyowa Kirin inked a commercialization and development deal with Kuro Oncology. Plus more.
By: Eric Sagonowsky
For many readers, the topics featured in this year's roundup of top stories won't come as much of a surprise.
(833) 317-6278 
